Cargando…

A phase II study of buparlisib in relapsed or refractory thymomas

PURPOSE: To investigate the efficacy and safety of buparlisib, an oral pan-PI3K inhibitor, in relapsed or refractory thymomas. METHODS: This was a single center, single arm, open label phase II trial of buparlisib in patients with recurrent thymoma who have progressed after at least one prior line o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abu Zaid, Mohammad I., Radovich, Milan, Althouse, Sandra, Liu, Hao, Spittler, Aaron J., Solzak, Jeffrey, Badve, Sunil, Loehrer, Patrick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623263/ https://www.ncbi.nlm.nih.gov/pubmed/36330484 http://dx.doi.org/10.3389/fonc.2022.891383

Ejemplares similares

A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas
por: Radovich, Milan, et al.
Publicado: (2016)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

Molecular Analysis of Thymoma
por: Badve, Sunil, et al.
Publicado: (2012)

A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study
por: Mamdani, Hirva, et al.
Publicado: (2021)

A Gene Signature to Determine Metastatic Behavior in Thymomas
por: Gökmen-Polar, Yesim, et al.
Publicado: (2013)

Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Shahda, Safi, et al.
Publicado: (2016)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019)

Thymomas With Intravascular and Intracardiac Growth
por: Arrossi, Andrea Valeria, et al.
Publicado: (2022)

Novel Treatments for Thymoma and Thymic Carcinoma
por: Rajan, Arun, et al.
Publicado: (2015)

Induction Strategy for Locally Advanced Thymoma
por: Zhang, Yang, et al.
Publicado: (2021)

Imaging Evaluation of Thymoma and Thymic Carcinoma
por: Strange, Chad D., et al.
Publicado: (2022)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
por: Chen, Yu-Hsiang, et al.
Publicado: (2017)

Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
por: Ladbury, Colton, et al.
Publicado: (2022)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib
por: Eismann, Julia, et al.
Publicado: (2019)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Managing Metastatic Thymoma With Metabolic and Medical Therapy: A Case Report
por: Phillips, Matthew C. L., et al.
Publicado: (2020)

Case report: Complex paraneoplastic syndromes in thymoma with nephrotic syndrome, cutaneous amyloidosis, myasthenia gravis, and Morvan’s syndrome
por: Liu, Huiqin, et al.
Publicado: (2022)

A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer
por: Subramaniam, Deepa S., et al.
Publicado: (2018)

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study
por: Ma, Jingjing, et al.
Publicado: (2022)

Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
por: Solzak, Jeffrey P., et al.
Publicado: (2017)

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
por: Rosenthal, Mark, et al.
Publicado: (2020)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
por: Tenold, Matthew E., et al.
Publicado: (2021)

Clinical and Genetic Characteristics of Thymoma Patients With Autoimmune Hepatitis and Myocarditis
por: Yu, Xin-tao, et al.
Publicado: (2022)

Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)
por: Song, Yuqin, et al.
Publicado: (2022)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
por: Zhang, Chengtao, et al.
Publicado: (2023)

Intrathymic growing bronchogenic cyst mimicking thymoma: A case report
por: Grigoroiu, Madalina, et al.
Publicado: (2023)

Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
por: Ueda, Masumi, et al.
Publicado: (2020)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
por: Wahab, Ahsan, et al.
Publicado: (2021)

Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
por: Barbanti, Maria Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_plfmc9lrt7k08k7o9g5b7ng8nm